Human CCL7/MCP-3/MARC Antibody
R&D Systems, part of Bio-Techne | Catalog # AB-282-NA
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Neutralization, Western Blot
Cited:
Neutralization
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
E. coli-derived recombinant human CCL7/MCP‑3/MARC
Gln24-109
Accession # P80098
Gln24-109
Accession # P80098
Specificity
Detects human CCL7/MCP‑3/MARC in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 6% cross-reactivity with recombinant human (rh) MCP-2 and rhMCP-1 is observed.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human CCL7/MCP-3/MARC Antibody
Chemotaxis Induced by CCL7/MCP‑3 and Neutral-ization by Human CCL7/MCP‑3 Antibody.
Recombinant Human CCL7/ MCP-3 (Catalog # 282-P3) chemoattracts human monocytes in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by LeukoStat™ staining (Fisher Scientific). Chemotaxis elicited by Recombinant Human CCL7/MCP-3 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CCL7/ MCP-3 Polyclonal Antibody (Catalog # AB-282-NA). The ND50 is typically 30-60 µg/mL.Applications for Human CCL7/MCP-3/MARC Antibody
Application
Recommended Usage
Western Blot
1 µg/mL
Sample: Recombinant Human CCL7/MCP-3/MARC (Catalog # 282-P3)
Sample: Recombinant Human CCL7/MCP-3/MARC (Catalog # 282-P3)
Neutralization
Measured by its ability to neutralize CCL7/MCP-3/MARC-induced chemotaxis in human monocytes. The Neutralization Dose (ND50) is typically 30-60 µg/mL in the presence of 0.1 µg/mL Recombinant Human CCL7/MCP-3/MARC.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 1 review rated 5 using AB-282-NA in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Reconstitution
Reconstitute at 1 mg/mL in sterile PBS.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CCL7/MCP-3/MARC
MCP-2 and CCL7 are two monocyte chemotactic proteins produced by human MG-63 osteosarcoma cells. Both MCP-2 and CCL7 are members of the C-C family of chemokines and share 62% and 71% amino acid sequence identity, respectively, with MCP-1. CCL7 also shares 58% amino acid identity with MCP-2.
CCL7 cDNA encodes a 99 amino acid residue precursor protein from which the N-terminal 23 amino acid residues are cleaved to generate the 76 amino acid residue mature CCL7. Mature CCL7 contains a potential N-linked and several possible O-linked glycosylation sites.
Similar to other C-C chemokines, all three MCP proteins are monocyte chemoattractants. In addition, the three MCPs can chemoattract activated NK cells as well as CD4+ and CD8+ T lymphocytes. All three cytokines have also been shown to attract eosinophils and induce histamine secretion from basophils.
Alternate Names
MARC, MCP-3
Gene Symbol
CCL7
UniProt
Additional CCL7/MCP-3/MARC Products
Product Documents for Human CCL7/MCP-3/MARC Antibody
Product Specific Notices for Human CCL7/MCP-3/MARC Antibody
For research use only
Loading...
Loading...
Loading...
Loading...